ZEALAND PHARMA A/S DK 1/ DK0060257814 /
9/5/2024 7:57:00 AM | Chg. -3.2000 | Volume | Bid8:51:43 AM | Ask8:51:43 AM | High | Low |
---|---|---|---|---|---|---|
113.5000EUR | -2.74% | - Turnover: - |
112.0000Bid Size: 34 | 112.9000Ask Size: 34 | 113.5000 | 113.5000 |
GlobeNewswire
8/22
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire
8/12
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial...
GlobeNewswire
6/26
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary share...
GlobeNewswire
6/25
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...
GlobeNewswire
6/25
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...
GlobeNewswire
6/20
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...
GlobeNewswire
6/7
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...
GlobeNewswire
6/7
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...
GlobeNewswire
6/6
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...
GlobeNewswire
5/31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
5/29
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
GlobeNewswire
5/23
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...
GlobeNewswire
5/9
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
3/20
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
2/26
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
2/26
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...